Congrats to R. Guggenberger, G. Wirnsberger and APEIRON Biologics founder Prof. Penninger. They report that all SARS-CoV-2 variants analyzed, including #VOC such as #Omicron , exhibit enhanced binding affinity to clinical grade #APN01 .

.APEIRON Biologics AG shareholders approve new group structure geared towards enabling innovation and growth:
invIOs becomes fully separate entity focused on advancing its unique #EPiC cell therapy platform and clinical-stage immuno-oncology pipeline bit.ly/3vpIlYJ

We are excited to join #BIOEuropeSpring for the first time with invIOs and to connect at this global meeting organized by EBD Group. E-meet us next week and learn more about invIOs' innovation hub and our unique approach to #cell_therapy .
invios.com

Join us tomorrow at Sachs European Life Sciences CEO Forum if you want to learn about our approach towards individualized cancer treatment! Do not miss our Spotlight Showcase tomorrow Tuesday, March 1st at 3:40 pm CET.
#Sachs_ELSF #lifesciences

#News : invIOs (innovative Immuno-Oncology) GmbH is pleased to announce it will commence operations on 1 January 2022.
Read more: bit.ly/3q40UgS
#newcompany #CancerResearch

Mario is Lead Scientist at invIOs and mainly responsible for INV441, our TILs project.

#team #cancerresearch #immunooncology #biotech #FacesOfInvios

Meet Andreas, Head of IT at invIOs. #Team #cancerresearch #biotech #FacesOfInvios

Romana is Chief Medical & Scientific Officer at invOs and responsible for the development of our drug candidate projects.

#team #cancerresearch #immunooncology #passionforwork #biotech

Only 5 days until invIOs goes live. Our todays face of invIOs is Alexander, Head of Research & Preclinical Development. Together with his team, he is responsible for the development of our immuno oncology therapeutics.
#cancerresearch #immunooncology #team #biotech

Removing the N-glycans of hACE2 increases its binding strength to Spike and makes it a better SARS-CoV-2 interceptor: doi.org/10.7554/eLife.…
Grand collaboration between 朴 正義 ☮️ Bascule Inc 🌏 KIBO宇宙放送局, Chris Oostenbrink, @biotop_phd, PenningerLab, @imba_vienna, @ubc, APEIRON Biologics AG, @medunigraz, Karolinska Institutet

#News : invIOs a fully owned subsidiary of APEIRON Biologics AG is pleased to announce it will commence operations on 1 January 2022.
Read more: bit.ly/3q40UgS
#newcompany #CancerResearch

Bei der Führung weder Scheu noch Scheuklappe haben sei entscheidend, sagt Romana Gugenberger, Vorständin für Forschung und Entwicklung beim Biotech-Unternehmen Apeiron. diepresse.com/6062918/pennin…

#Job : Looking for a challenge at the intersection of Science and Business? We are currently recruiting a (Junior) Legal Counsel. Join a highly motivated team with high ambitions.
Find our more: apeiron-biologics.com/career/
#HIRINGNOW #legal #Science #lifesciences

APEIRON Biologics AG has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.

ddw-online.com/apeiron-biolog…

#Covid19

Follow us on The Cancer Revolution. Read on characteristics which cancer cells acquire during the development of tumors. Learn more on challenges ahead for cancer therapy.
apeiron-biologics.com/the-cancer-rev…

#Cancer #Oncology #Cancer Research #Cancer Awareness

#Apeiron testet #Covid19 - #Medikament -Kandidat zur #Inhalation in Wien go.apa.at/vsI6g1PW APEIRON Biologics AG MedUni Wien #Studie

#News : APEIRON Biologics today announced the start of a company sponsored Phase 1 clinical #COVID19 trial for inhalation of APN01. Primary objective is to evaluate safety and tolerability of inhaled APN01. Read more:
apeiron-biologics.com/apeiron-biolog…
#covid19therapy #SARSCoV2 #inhalation

We have discussed the role of #ACE2 within the RAAS and the #therapeutical potential of a recombinant soluble ACE2 for COVID-19 patients with Prof. Josef Penninger.
Read here our 3 Questions to Prof. Josef Penninger: bit.ly/3tIzNcF

#COVID19 #SARSCoV2 #3Questions2

Congratulations to @eusapharma and BeiGene for reaching this major milestone. QARZIBA® (Dinutuximab Beta) is now approved in #China for the treatment of high-risk #neuroblastoma in patients aged 12 months and above.
#immunotherapy #cancer

Congratulations to @eusapharma and BeiGene for reaching this major milestone. QARZIBA® (Dinutuximab Beta) is now approved in #China for the treatment of high-risk #neuroblastoma in patients aged 12 months and above.
#immunotherapy #cancer